Developer docs
API playgroundTry for free, no card

Search company profiles

Penuma

Full company profile

uuid002lyzk

Namestring
Penuma
Legal namestring
Himplant
Websiteurl
penuma.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Penuma, operating commercially as Himplant, is a Beverly Hills-based medical device company founded in 2004 that developed the first FDA-cleared silicone penile implant for cosmetic male enhancement. The core product, Himplant®, is a soft medical-grade silicone implant designed to deliver an average girth increase of 1-2 inches with potential improvements in flaccid length, and is backed by a limited lifetime warranty. The company complements the implant with the Himplant POV mobile app, an AI-powered simulation tool available on iOS and Android that generates personalized before-and-after previews from a single front-angle photograph.

The business operates a direct-to-consumer model in which prospective patients complete an online eligibility screening (with provisional clearance typically within three days) and are then routed to a network of trained physicians. Procedures are one-time surgical events priced at $10,500-$19,000, with average pricing of $13,000-$19,000, and patients may add procedures such as circumcision or suprapubic fat removal. Revenue is generated entirely through surgical procedure fees performed by network physicians, and Penuma monetizes by supplying the implant and supporting the physician network rather than operating clinics directly.

The company has expanded beyond its Beverly Hills headquarters under the leadership of Dr. James Elist, the implant's inventor, building a global provider network across multiple U.S. metropolitan areas and international markets including Dubai (UAE), Riyadh (Saudi Arabia), Amman (Jordan), Istanbul (Turkey), and several Latin American countries (Colombia, Mexico, Chile). Marketing is multi-channel, combining a knowledge hub ("HimFACTS"), before/after galleries and testimonials, a physician finder, earned media in outlets such as Men's Health and BuzzFeed, and the AI-powered POV app as a top-of-funnel engagement tool.

Short descriptiontext

Penuma (operating as Himplant) is a Beverly Hills-based medical device company that developed the first FDA-cleared silicone penile implant for cosmetic male enhancement, selling through a global network of trained physicians at $10,500-$19,000 per procedure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBeverly Hills, United States
HQ citystring
Beverly Hills
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cosmetic penile implants, male enhancement surgery, medical device aesthetics, FDA-cleared silicone implants, urological cosmetic surgery
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Cosmetic urology medical devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Surgical Procedure Revenue
TypeOne Time License
Description

One-time surgical procedure fees for penile implant surgery. Cost varies based on patient anatomy, surgeon, and add-on procedures (e.g., circumcision, suprapubic fat removal). Most patients pay $10,500–$19,000 with average pricing at $13,000–$19,000.

himplant.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Marketing or Sales, Personnel, Technology or R&D, Supply Chain
Pricing details1 tier
1Himplant® Cosmetic Penile Enhancement Surgery
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$10,500–$19,000 total cost; Average price: $13,000–$19,000. Price varies by anatomy, surgeon, and add-on procedures.

himplant.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Himplant® POV App
Description

AI-powered simulation app that provides realistic previews of Himplant® results before and after procedures

himplant.com
Core offering1 text field

Penuma develops, manufactures, and distributes the Himplant® penile implant — the first FDA-cleared silicone implant for cosmetic male enhancement — delivering an average 1–2 inch girth increase with a concealed scar, removable design, and limited lifetime warranty. The implant is delivered through a global network of trained surgeons across the United States, Middle East, Latin America, and Europe, with patients typically paying a one-time surgical fee of $10,500–$19,000. The company also offers the Himplant POV App, an AI-powered mobile simulation tool that shows prospective patients personalized before-and-after previews before they commit to surgery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Average girth increase of 1-2 inches observed across thousands of patients
+1 more record
Product overview1 text field

Penuma offers the Himplant® as its core product — the world's first FDA-cleared penile implant for cosmetic male enhancement, made from soft medical-grade silicone. The company complements this with the Himplant POV App, an AI-powered simulation tool that allows prospective patients to visualize potential results before committing to the procedure. Pricing ranges from $10,500–$19,000 with an average of $13,000–$19,000, and the implant includes a limited lifetime warranty.

Product and service2 records
1Himplant® Penile Implant
CategoryCosmetic urology medical device and implantation surgery
Description

The world's first FDA-cleared penile implant for cosmetic male enhancement, made from soft medical-grade silicone to deliver an average girth increase of 1–2 inches with potential improvements in flaccid length, a concealed scar, and a removable design covered by a limited lifetime warranty; intended for adult men seeking elective cosmetic enhancement and implanted by trained physicians across the company's global provider network.

2Himplant POV App
CategoryPatient engagement and simulation mobile application
Description

Private, AI-powered mobile application available on iOS and Android that takes a user-uploaded front-angle photo and generates a realistic personalized before-and-after simulation preview of potential Himplant® results without requiring commitment to surgery; intended for prospective patients in the top-of-funnel research and consideration phase.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Direct-to-consumer men's health and wellness platform offering telehealth, prescription treatments, and consumer products. Comparable as a D2C men's wellness brand reaching the same end-demographic via online acquisition funnels, though focused on non-implant offerings.

2Ro
TypeEmerging player
Description

Direct-to-consumer digital health company operating men's health (Roman) and women's health brands with telehealth and prescription fulfillment. Comparable for its D2C men's wellness positioning and online conversion model even though it does not sell implants.

TypeBroad incumbent
Description

Medical technology company focused on breast implant aesthetics and reconstruction. Comparable as a premium cosmetic implant company with a similar FDA-clearance-driven positioning in elective aesthetic surgery and a physician-network distribution model.

TypeDirect peer
Description

Global medical device company that manufactures silicone penile implants (Titan, Genesis) primarily for erectile dysfunction treatment. Directly comparable as another manufacturer of silicone penile prostheses with physician-driven distribution, though Coloplast targets functional rather than cosmetic use.

TypeBroad incumbent
Description

Global pharmaceutical and aesthetics major that owns Allergan Aesthetics, a broad portfolio of cosmetic implants, fillers, and body-contouring products. Comparable as a broader incumbent in cosmetic implantable devices, though it does not focus on penile implants.

TypeDirect peer
Description

Medical device major that sells penile implants through its AMS (American Medical Systems) portfolio (AMS 700, Ambicor). Comparable as a direct penile implant competitor with established physician relationships, regulatory infrastructure, and broader urology scale.

TypeDirect peer
Description

Swiss manufacturer of malleable and inflatable penile implants marketed internationally. Directly comparable as a specialty penile implant competitor targeting similar urology and aesthetic physician networks across multiple geographies.

TypeBroad incumbent
Description

Global dermatology and aesthetics company offering injectable aesthetics, skincare, and therapeutic dermatology products. Comparable as a broad aesthetics incumbent with adjacent men's wellness and procedural offerings, though not focused on implants.

TypeBroad incumbent
Description

Medical aesthetics company selling breast implants and other body-contouring products through board-certified plastic surgeons. Comparable as a focused cosmetic implant manufacturer leveraging a physician-network distribution model similar to Penuma's.

TypeDirect peer
Description

Specialty urological implant company offering inflatable and malleable penile prostheses (Infla10, Rigi10). Directly comparable as a focused penile implant manufacturer competing for similar physician customers globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Penuma

Cosmetic urology medical devicespenuma.com

Penuma (operating as Himplant) is a Beverly Hills-based medical device company that developed the first FDA-cleared silicone penile implant for cosmetic male enhancement, selling through a global network of trained physicians at $10,500-$19,000 per procedure.

What Penuma does

Penuma, operating commercially as Himplant, is a Beverly Hills-based medical device company founded in 2004 that developed the first FDA-cleared silicone penile implant for cosmetic male enhancement. The core product, Himplant®, is a soft medical-grade silicone implant designed to deliver an average girth increase of 1-2 inches with potential improvements in flaccid length, and is backed by a limited lifetime warranty. The company complements the implant with the Himplant POV mobile app, an AI-powered simulation tool available on iOS and Android that generates personalized before-and-after previews from a single front-angle photograph.

The business operates a direct-to-consumer model in which prospective patients complete an online eligibility screening (with provisional clearance typically within three days) and are then routed to a network of trained physicians. Procedures are one-time surgical events priced at $10,500-$19,000, with average pricing of $13,000-$19,000, and patients may add procedures such as circumcision or suprapubic fat removal. Revenue is generated entirely through surgical procedure fees performed by network physicians, and Penuma monetizes by supplying the implant and supporting the physician network rather than operating clinics directly.

The company has expanded beyond its Beverly Hills headquarters under the leadership of Dr. James Elist, the implant's inventor, building a global provider network across multiple U.S. metropolitan areas and international markets including Dubai (UAE), Riyadh (Saudi Arabia), Amman (Jordan), Istanbul (Turkey), and several Latin American countries (Colombia, Mexico, Chile). Marketing is multi-channel, combining a knowledge hub ("HimFACTS"), before/after galleries and testimonials, a physician finder, earned media in outlets such as Men's Health and BuzzFeed, and the AI-powered POV app as a top-of-funnel engagement tool.

Penuma firmographics

Firmographics
Name
Penuma
Legal name
Himplant
Website
https://penuma.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1–10 employees
Short description
Penuma (operating as Himplant) is a Beverly Hills-based medical device company that developed the first FDA-cleared silicone penile implant for cosmetic male enhancement, selling through a global network of trained physicians at $10,500-$19,000 per procedure.
Ownership category
akta.pro rank

Where Penuma is headquartered

Location

Headquarters

HQ city
Beverly Hills
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Penuma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Marketing or Sales, Personnel, Technology or R&D, Supply Chain

Revenue model

  1. Surgical Procedure Revenue: One-time surgical procedure fees for penile implant surgery. Cost varies based on patient anatomy, surgeon, and add-on procedures (e.g., circumcision, suprapubic fat removal). Most patients pay $10,500–$19,000 with average pricing at $13,000–$19,000.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goHimplant® Cosmetic Penile Enhancement Surgery

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Penuma product offering

Product offering

Core offering

Penuma develops, manufactures, and distributes the Himplant® penile implant — the first FDA-cleared silicone implant for cosmetic male enhancement — delivering an average 1–2 inch girth increase with a concealed scar, removable design, and limited lifetime warranty. The implant is delivered through a global network of trained surgeons across the United States, Middle East, Latin America, and Europe, with patients typically paying a one-time surgical fee of $10,500–$19,000. The company also offers the Himplant POV App, an AI-powered mobile simulation tool that shows prospective patients personalized before-and-after previews before they commit to surgery.

Product overview

Penuma offers the Himplant® as its core product — the world's first FDA-cleared penile implant for cosmetic male enhancement, made from soft medical-grade silicone. The company complements this with the Himplant POV App, an AI-powered simulation tool that allows prospective patients to visualize potential results before committing to the procedure. Pricing ranges from $10,500–$19,000 with an average of $13,000–$19,000, and the implant includes a limited lifetime warranty.

Differentiator

Problem solved

Functional benefit

Brands

  • Himplant® POV App: AI-powered simulation app that provides realistic previews of Himplant® results before and after procedures

Products and services

  • Himplant® Penile Implant The world's first FDA-cleared penile implant for cosmetic male enhancement, made from soft medical-grade silicone to deliver an average girth increase of 1–2 inches with potential improvements in flaccid length, a concealed scar, and a removable design covered by a limited lifetime warranty; intended for adult men seeking elective cosmetic enhancement and implanted by trained physicians across the company's global provider network.
  • Himplant POV App Private, AI-powered mobile application available on iOS and Android that takes a user-uploaded front-angle photo and generates a realistic personalized before-and-after simulation preview of potential Himplant® results without requiring commitment to surgery; intended for prospective patients in the top-of-funnel research and consideration phase.

Quantifiable outcome

  • Average girth increase of 1-2 inches observed across thousands of patients
  • +1 more outcomes

Companies that use Penuma

Customer profile

Segments1 record

Ideal customer profiles2 records

Penuma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Penuma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Penuma competitors and assessment

Company assessment

Emerging players

  • Hims & Hers Health: Direct-to-consumer men's health and wellness platform offering telehealth, prescription treatments, and consumer products. Comparable as a D2C men's wellness brand reaching the same end-demographic via online acquisition funnels, though focused on non-implant offerings.
  • Ro: Direct-to-consumer digital health company operating men's health (Roman) and women's health brands with telehealth and prescription fulfillment. Comparable for its D2C men's wellness positioning and online conversion model even though it does not sell implants.

Broad incumbents

  • Establishment Labs: Medical technology company focused on breast implant aesthetics and reconstruction. Comparable as a premium cosmetic implant company with a similar FDA-clearance-driven positioning in elective aesthetic surgery and a physician-network distribution model.
  • AbbVie (Allergan Aesthetics): Global pharmaceutical and aesthetics major that owns Allergan Aesthetics, a broad portfolio of cosmetic implants, fillers, and body-contouring products. Comparable as a broader incumbent in cosmetic implantable devices, though it does not focus on penile implants.
  • Galderma: Global dermatology and aesthetics company offering injectable aesthetics, skincare, and therapeutic dermatology products. Comparable as a broad aesthetics incumbent with adjacent men's wellness and procedural offerings, though not focused on implants.
  • Sientra: Medical aesthetics company selling breast implants and other body-contouring products through board-certified plastic surgeons. Comparable as a focused cosmetic implant manufacturer leveraging a physician-network distribution model similar to Penuma's.

Direct peers

  • Coloplast: Global medical device company that manufactures silicone penile implants (Titan, Genesis) primarily for erectile dysfunction treatment. Directly comparable as another manufacturer of silicone penile prostheses with physician-driven distribution, though Coloplast targets functional rather than cosmetic use.
  • Boston Scientific: Medical device major that sells penile implants through its AMS (American Medical Systems) portfolio (AMS 700, Ambicor). Comparable as a direct penile implant competitor with established physician relationships, regulatory infrastructure, and broader urology scale.
  • Zephyr Surgical Implants: Swiss manufacturer of malleable and inflatable penile implants marketed internationally. Directly comparable as a specialty penile implant competitor targeting similar urology and aesthetic physician networks across multiple geographies.
  • Rigicon: Specialty urological implant company offering inflatable and malleable penile prostheses (Infla10, Rigi10). Directly comparable as a focused penile implant manufacturer competing for similar physician customers globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Penuma social profiles

Digital presence

Penuma compliance and trust

Trust signal

Compliance3 records

Penuma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Penuma leadership team

Management profile

Number of profiles

Profiles1 record

Penuma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Penuma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Penuma

What does Penuma do?

Penuma develops, manufactures, and distributes the Himplant® penile implant — the first FDA-cleared silicone implant for cosmetic male enhancement — delivering an average 1–2 inch girth increase with a concealed scar, removable design, and limited lifetime warranty. The implant is delivered through a global network of trained surgeons across the United States, Middle East, Latin America, and Europe, with patients typically paying a one-time surgical fee of $10,500–$19,000. The company also offers the Himplant POV App, an AI-powered mobile simulation tool that shows prospective patients personalized before-and-after previews before they commit to surgery.

Is Penuma a public or private company?

Penuma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Penuma founded?

Penuma was founded in 2004. It employs 1 to 10 people.

Where is Penuma based?

Penuma is headquartered in Beverly Hills, United States, in the North America region.

How does Penuma make money?

One revenue line is on record: surgical Procedure Revenue.

Who are Penuma's main competitors?

Emerging players on record are Hims & Hers Health and Ro. Broad incumbents are Establishment Labs, AbbVie (Allergan Aesthetics), Galderma and Sientra. Direct peers are Coloplast, Boston Scientific, Zephyr Surgical Implants and Rigicon.

Does Penuma have an API?

No public API is recorded for Penuma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals